676 related articles for article (PubMed ID: 15316862)
1. Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation.
Ishida M; Amano S
J Bone Miner Metab; 2004; 22(5):415-29. PubMed ID: 15316862
[TBL] [Abstract][Full Text] [Related]
2. Effect of high phosphate concentration on osteoclast differentiation as well as bone-resorbing activity.
Kanatani M; Sugimoto T; Kano J; Kanzawa M; Chihara K
J Cell Physiol; 2003 Jul; 196(1):180-9. PubMed ID: 12767054
[TBL] [Abstract][Full Text] [Related]
3. MLO-Y4 osteocyte-like cells support osteoclast formation and activation.
Zhao S; Zhang YK; Harris S; Ahuja SS; Bonewald LF
J Bone Miner Res; 2002 Nov; 17(11):2068-79. PubMed ID: 12412815
[TBL] [Abstract][Full Text] [Related]
4. Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors.
Shalhoub V; Faust J; Boyle WJ; Dunstan CR; Kelley M; Kaufman S; Scully S; Van G; Lacey DL
J Cell Biochem; 1999 Feb; 72(2):251-61. PubMed ID: 10022507
[TBL] [Abstract][Full Text] [Related]
5. Statins modulate the levels of osteoprotegerin/receptor activator of NFkappaB ligand mRNA in mouse bone-cell cultures.
Kaji H; Kanatani M; Sugimoto T; Chihara K
Horm Metab Res; 2005 Oct; 37(10):589-92. PubMed ID: 16278780
[TBL] [Abstract][Full Text] [Related]
6. Microrough implant surface topographies increase osteogenesis by reducing osteoclast formation and activity.
Lossdörfer S; Schwartz Z; Wang L; Lohmann CH; Turner JD; Wieland M; Cochran DL; Boyan BD
J Biomed Mater Res A; 2004 Sep; 70(3):361-9. PubMed ID: 15293309
[TBL] [Abstract][Full Text] [Related]
7. Human trabecular bone-derived osteoblasts support human osteoclast formation in vitro in a defined, serum-free medium.
Atkins GJ; Kostakis P; Welldon KJ; Vincent C; Findlay DM; Zannettino AC
J Cell Physiol; 2005 Jun; 203(3):573-82. PubMed ID: 15573398
[TBL] [Abstract][Full Text] [Related]
8. Lipopolysaccharide from Prevotella nigrescens stimulates osteoclastogenesis in cocultures of bone marrow mononuclear cells and primary osteoblasts.
Chung YH; Chang EJ; Kim SJ; Kim HH; Kim HM; Lee SB; Ko JS
J Periodontal Res; 2006 Aug; 41(4):288-96. PubMed ID: 16827722
[TBL] [Abstract][Full Text] [Related]
9. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
Xiao XH; Zhou HD; Yuan LQ; Xie H; Liao EY
Zhonghua Yi Xue Za Zhi; 2004 Dec; 84(24):2102-6. PubMed ID: 15730627
[TBL] [Abstract][Full Text] [Related]
10. Thyroid hormone stimulates osteoclast differentiation by a mechanism independent of RANKL-RANK interaction.
Kanatani M; Sugimoto T; Sowa H; Kobayashi T; Kanzawa M; Chihara K
J Cell Physiol; 2004 Oct; 201(1):17-25. PubMed ID: 15281085
[TBL] [Abstract][Full Text] [Related]
11. Suramin interacts with RANK and inhibits RANKL-induced osteoclast differentiation.
Regmi A; Fuson T; Yang X; Kays J; Moxham C; Zartler E; Chandrashekhar S; Galvin RJ
Bone; 2005 Feb; 36(2):284-91. PubMed ID: 15780954
[TBL] [Abstract][Full Text] [Related]
12. Pulsed electromagnetic fields stimulation affects osteoclast formation by modulation of osteoprotegerin, RANK ligand and macrophage colony-stimulating factor.
Chang K; Chang WH; Huang S; Huang S; Shih C
J Orthop Res; 2005 Nov; 23(6):1308-14. PubMed ID: 15913941
[TBL] [Abstract][Full Text] [Related]
13. c-Fos protein as a target of anti-osteoclastogenic action of vitamin D, and synthesis of new analogs.
Takasu H; Sugita A; Uchiyama Y; Katagiri N; Okazaki M; Ogata E; Ikeda K
J Clin Invest; 2006 Feb; 116(2):528-35. PubMed ID: 16424941
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effect of beta-cryptoxanthin on osteoclast-like cell formation in mouse marrow cultures.
Uchiyama S; Yamaguchi M
Biochem Pharmacol; 2004 Apr; 67(7):1297-305. PubMed ID: 15013845
[TBL] [Abstract][Full Text] [Related]
15. Potential role of cbfa1, an essential transcriptional factor for osteoblast differentiation, in osteoclastogenesis: regulation of mRNA expression of osteoclast differentiation factor (ODF).
Gao YH; Shinki T; Yuasa T; Kataoka-Enomoto H; Komori T; Suda T; Yamaguchi A
Biochem Biophys Res Commun; 1998 Nov; 252(3):697-702. PubMed ID: 9837769
[TBL] [Abstract][Full Text] [Related]
16. Regulation of osteoclastogenesis by gap junction communication.
Matemba SF; Lie A; Ransjö M
J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
[TBL] [Abstract][Full Text] [Related]
17. Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function.
Udagawa N; Takahashi N; Yasuda H; Mizuno A; Itoh K; Ueno Y; Shinki T; Gillespie MT; Martin TJ; Higashio K; Suda T
Endocrinology; 2000 Sep; 141(9):3478-84. PubMed ID: 10965921
[TBL] [Abstract][Full Text] [Related]
18. Osteoclastogenesis is decreased by cysteine proteinase inhibitors.
Brage M; Lie A; Ransjö M; Kasprzykowski F; Kasprzykowska R; Abrahamson M; Grubb A; Lerner UH
Bone; 2004 Mar; 34(3):412-24. PubMed ID: 15003789
[TBL] [Abstract][Full Text] [Related]
19. Cloning, sequencing, and functional characterization of the rat homologue of receptor activator of NF-kappaB ligand.
Xu J; Tan JW; Huang L; Gao XH; Laird R; Liu D; Wysocki S; Zheng MH
J Bone Miner Res; 2000 Nov; 15(11):2178-86. PubMed ID: 11092398
[TBL] [Abstract][Full Text] [Related]
20. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells.
Fujisaki K; Tanabe N; Suzuki N; Kawato T; Takeichi O; Tsuzukibashi O; Makimura M; Ito K; Maeno M
Life Sci; 2007 Mar; 80(14):1311-8. PubMed ID: 17306833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
